Valuation dashboard for Novo Nordisk A/S (NVO) with P/E 9.36, P/B 4.91, EV/EBITDA 6.89 and dividend yield 4.77%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease.
Analysis Summary
Novo Nordisk A/S reported revenue of 309.06B DKK in the most recent fiscal year, growing at a 5-year CAGR of 19.5%. Net income reached 102.43B DKK, with a 19.4% 5-year CAGR.
Trailing-twelve-month margins: gross margin 80.6%, operating margin 43.1%, net margin 35.3%.
At the current price of $37.54, NVO trades at a P/E of 9.36 and an ROE of 59.09%. Market capitalisation stands at $166.7B, placing it among large-cap names.
Balance sheet quality for NVO: current ratio of 0.8. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 9.36 |
| Price / Book | 4.91 |
| EV / EBITDA | 6.89 |
| Dividend Yield | 4.77% |
Valuation Models
| DCF Fair Value | $73.84 |
| vs Current Price | +96.7% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NVO | Novo Nordisk A/S | $170.1B | 9.36 | 4.91 | 59.1% |
| MRK | Merck & Co., Inc. | $356.4B | 115.44 | 8.51 | 6.6% |
| AMGN | Amgen Inc. | $217.5B | 25.05 | 18.62 | 89.1% |
| GILD | Gilead Sciences, Inc. | $179.5B | 15.21 | -16.3% | |
| AZN | AstraZeneca PLC | $252.8B | 23.36 | 4.81 | 21.7% |
| NVS | Novartis AG | $271.0B | 21.30 | 6.42 | 30.5% |
| ABT | Abbott Laboratories | $168.7B | 31.35 | 3.33 | 12.5% |
| PFE | Pfizer Inc. | $158.4B | 36.73 | 1.86 | 9.0% |
Price
| Price | $37.54 |
| Market Cap | $166.7B |
| Exchange | NYSE |
| Country | DK |
Profitability
| Return on Equity | 59.09% |
| Return on Invested Capital | 29.73% |
| Return on Assets | 19.57% |
| Gross Margin | 80.65% |
| Operating Margin | 43.13% |
| Net Margin | 35.35% |
Related companies: ABT · AMGN · AZN · GILD · GSK · MRK · NVS
Explore sector: Healthcare · Drug Manufacturers - General
More sections of NVO: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks